TP-110

TP-110 is a proteasome inhibitor. TP-110 specifically inhibits the protease-like activity of the 20S proteasome, but does not affect the trypsin-like or peptidyl-glutamyl peptide hydrolysis activity. TP-110 inhibits the NF-κB pathway, activates caspase-8, -9, and -3, and causes PARP cleavage, significantly reducing the levels of cIAP-1 and XIAP. TP-110 causes cell cycle arrest at the G2/M phase and promotes apoptosis of cancer cells. TP-110 can be used in cancer research of prostate cancer and multiple myeloma, etc[1][2].

Product Specifications

CAS Number

[688737-95-3]

UNSPSC

12352005

Target

Apoptosis; Caspase; IAP; NF-κB; PARP; Proteasome

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

CC([C@@H](C(N)=O)N(C([C@H](CC1=CC=C(C=C1)OC)NC(CC2=C3C=CC=CC3=CC=C2)=O)=O)C(CC4=CC=C(C=C4)OC)C=O)C

Molecular Formula

C37H41N3O6

Molecular Weight

623.74

References & Citations

[1]Iijima M, Momose I, Ikeda D. TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cells. Anticancer Res. 2009 Apr;29 (4) :977-85.|[2]Momose I, et al. A new proteasome inhibitor, TP-110, induces apoptosis in human prostate cancer PC-3 cells. Biosci Biotechnol Biochem. 2007 Apr;71 (4) :1036-43.